Type 2 diabetes mellitus

25 trials 7 recruiting MedDRA PT
25 Registered trials
7 Recruiting
21 Unique sponsors
25 Unique IMPs
17 Commercial trials
Drug classes (ATC)
— ATC code not specified 18
A Gastroenterology (ATC A) 6
B Haematology (ATC B) 1
C Cardiology (ATC C) 2
V Various (ATC V) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 14 substances
SGLT2 inhibitor 3 substances
DPP-4 inhibitor 3 substances
GLP-1 receptor agonist 2 substances
Beta-blocker 2 substances
Antiplatelet / NSAID 1 substance
Phase III: 3 Phase II: 4 Phase IV: 4 Phase I: 1 Phase I (Other): 7 Phase I (First in Human): 1 Other: 5

Filter these 25 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 25 trials

Phase III

3 trials
  • Institut De Recherches Internationales Servier IRIS Commercial
    DAPAGLIFLOZIN; GLICLAZIDE
    2024-511408-18-00 5 countries 2024 n=242
    Ended
  • Assistance Publique Hopitaux De Paris Academic
    ALLOGENEIC FAECAL MICROBIOTA, POOLED; PLACEBO
    2024-511870-65-00 1 country 2024 n=94
    Recruiting
  • Casa Di Cura Accreditata Istituto Chirurgico Ortopedico Traumatologico Marco Pasquali Academic
    ACETYLSALICYLIC ACID; CLOPIDOGREL; SEMAGLUTIDE
    2025-522486-29-01 1 country n=212
    Pending

Phase II

4 trials
  • Amgen Inc. Commercial
    MARIDEBART CAFRAGLUTIDE
    2024-513539-25-00 8 countries 2024 n=219
    Ended
  • Corxel Pharmaceuticals Co. Ltd. Commercial
    CX11 TROMETAMOL MONOHYDRATE
    2025-524514-28-00 1 country 2026 n=121
    Recruiting
  • Bispebjerg Hospital Academic
    SEMAGLUTIDE
    2023-504913-65-01 1 country 2026 n=100
    Recruiting
  • Kantonsspital Baden AG Academic
    DAPANSUTRILE
    2024-511828-14-00 3 countries 2025 n=230
    Recruiting

Phase IV

4 trials
  • Aarhus University Hospital Academic
    ATENOLOL; DAPAGLIFLOZIN; GLYCERYL TRINITRATE; IOMEPROL; IVABRADINE; METOPROLOL TARTRATE; SEMAGLUTIDE
    2022-500143-21-01 1 country 2023 n=7,300
    Ended
  • Aarhus University Hospital Academic
    FINERENONE
    2023-504446-58-00 1 country 2024 n=80
    Recruiting
  • Instituto De Investigacion Sanitaria Fundacion Para La Investigacion Del Hospital Clinico De Valencia-INCLIVA Academic
    CANAGLIFLOZIN; DAPAGLIFLOZIN; DULAGLUTIDE; EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE; PIOGLITAZONE; SEMAGLUTIDE; SITAGLIPTIN; VILDAGLIPTIN
    2025-520686-46-00 1 country 2025 n=504
    Ended
  • Universita' Degli Studi Di Napoli Federico II Academic
    IMP not specified
    2025-520802-37-00 1 country n=80
    Pending

Phase I

1 trial
  • AC Immune S.A. Commercial
    IMP not specified
    2025-523885-25-00 1 country 2026 n=114
    Recruiting

Phase I (Other)

7 trials
  • AstraZeneca AB Commercial
    IMP not specified
    2025-522551-25-00 1 country 2026 n=35
    Halted
  • Eli Lilly & Co. Commercial
    IMP not specified
    2023-508008-39-00 1 country 2023 n=70
    Ended
  • F. Hoffmann-La Roche AG Commercial
    IMP not specified
    2025-521401-41-00 1 country 2025 n=30
    Ended
  • Gan & Lee Pharmaceuticals USA Corp. Commercial
    IMP not specified
    2024-519646-73-00 1 country n=14
    Ended
  • Gan & Lee Pharmaceuticals USA Corp. Commercial
    IMP not specified
    2025-522662-67-00 1 country 2025 n=14
    Recruiting
  • Institut De Recherches Internationales Servier IRIS Commercial
    GLICLAZIDE
    2023-507802-15-00 1 country 2023 n=68
    Ended
  • Novo Nordisk A/S Commercial
    IMP not specified
    2023-509961-19-00 1 country 2024 n=42
    Ended

Phase I (First in Human)

1 trial
  • Alnylam Pharmaceuticals Inc. Commercial
    ALN-4324
    2024-519005-35-00 2 countries 2026 n=35
    Ended

Other

5 trials
  • Adamed Pharma S.A. Commercial
    IMP not specified
    2025-522975-27-00 1 country 2025 n=44
    Ended
  • Adamed Pharma S.A. Commercial
    IMP not specified
    2025-522976-10-00 1 country 2025 n=44
    Ended
  • Laboratorios Cinfa S.A. Commercial
    IMP not specified
    2025-522234-31-00 1 country 2025 n=32
    Ended
  • Tarchominskie Zaklady Farmaceutyczne Polfa S.A. Commercial
    IMP not specified
    2026-525434-33-00 1 country 2026 n=32
    Ended
  • Vipharm S.A. Commercial
    IMP not specified
    2026-526840-10-00 1 country n=40
    Pending
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Adamed Pharma S.A. Commercial 2 Other 0
Gan & Lee Pharmaceuticals USA Corp. Commercial 2 Phase I (Other) 1
Institut De Recherches Internationales Servier IRIS Commercial 2 Phase I (Other), Phase III 0
Aarhus University Hospital Academic 2 Phase IV 1
AC Immune S.A. Commercial 1 Phase I 1
Laboratorios Cinfa S.A. Commercial 1 Other 0
Tarchominskie Zaklady Farmaceutyczne Polfa S.A. Commercial 1 Other 0
Vipharm S.A. Commercial 1 Other 0
AstraZeneca AB Commercial 1 Phase I (Other) 0
Eli Lilly & Co. Commercial 1 Phase I (Other) 0
F. Hoffmann-La Roche AG Commercial 1 Phase I (Other) 0
Novo Nordisk A/S Commercial 1 Phase I (Other) 0
Amgen Inc. Commercial 1 Phase II 0
Corxel Pharmaceuticals Co. Ltd. Commercial 1 Phase II 1
Alnylam Pharmaceuticals Inc. Commercial 1 Phase I (First in Human) 0
Bispebjerg Hospital Academic 1 Phase II 1
Kantonsspital Baden AG Academic 1 Phase II 1
Assistance Publique Hopitaux De Paris Academic 1 Phase III 1
Casa Di Cura Accreditata Istituto Chirurgico Ortopedico Traumatologico Marco Pasquali Academic 1 Phase III 0
Instituto De Investigacion Sanitaria Fundacion Para La Investigacion Del Hospital Clinico De Valencia-INCLIVA Academic 1 Phase IV 0
New trials by year
2023
3
2024
5
2025
7
2026
6
← All indication landscapes